Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the
specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with
progressive supranuclear palsy (PSP).